8-K: Microbot Medical Closes $13 Million Registered Direct Offering

Microbot Medical successfully closes a $13 million registered direct offering and concurrent private placement to fund the development and commercialization of its LIBERTY Robotic System.

Summary

• Microbot Medical Inc. closed a registered direct offering priced at-the-market, selling 6,103,289 shares of common stock at $2.13 per share.
• The company also completed a concurrent private placement, issuing investment options to purchase up to 12,206,578 shares at an exercise price of $2.13 per share.
• The gross proceeds from both offerings totaled approximately $13 million before deducting fees and expenses.
• Microbot Medical intends to use the net proceeds to advance the LIBERTY Robotic System, expand its IP portfolio, and for general corporate purposes.

Sentiment

Score: 7

Explanation: The announcement is positive as it secures funding for the company's key projects, but the reliance on capital raises also indicates a need for ongoing financial support.

Positives

• The successful completion of the $13 million offering strengthens Microbot Medical's financial position.
• The proceeds will be used to advance the development and commercialization of the LIBERTY Robotic System, a key product for the company.
• The offering provides capital for expanding the company's IP portfolio and for general corporate purposes.

Risks

• The company's future success depends on the successful development and commercialization of the LIBERTY Endovascular Robotic Surgical System.
• The company needs to obtain additional working capital to continue its transition to a commercially focused company.
• The company faces risks inherent in the development and/or commercialization of the LIBERTY Endovascular Robotic Surgical System.
• The company faces uncertainty in the results of regulatory pathways and regulatory approvals, including whether the FDA will grant 510(k) clearance to commercially market the LIBERTY Endovascular Robotic Surgical System in the United States.
• The company faces disruptions resulting from new and ongoing hostilities between Israel and the Palestinians and other neighboring countries.
• The company needs to obtain future capital, and maintenance of intellectual property rights.

Future Outlook

The company intends to use the net proceeds from the offerings for the continued development, commercialization and regulatory activities for the Company's LIBERTY Robotic System, expansion and development of additional applications derived from the Company's existing IP portfolio, and for working capital and other general corporate purposes.

Industry Context

The funding will allow Microbot Medical to continue its work in the competitive medical robotics field, where companies are striving to develop less invasive and more precise surgical tools.

Comparison to Industry Standards

• The $13 million raised is a moderate amount compared to funding rounds of larger medical device companies, but it is significant for a company of Microbot Medical's size and stage.
• Comparable companies in the medical robotics space, such as Intuitive Surgical and Stryker, have significantly larger market capitalizations and R&D budgets.

Stakeholder Impact

• Shareholders will be impacted by the dilution from the issuance of new shares.
• The funding supports the company's ability to continue operations and develop its technology, potentially benefiting employees.
• Successful development of the LIBERTY Robotic System could improve patient care and outcomes.

Next Steps

• Microbot Medical will use the funds to continue developing and commercializing the LIBERTY Robotic System.
• The company will seek stockholder approval for increasing authorized shares and issuing series I preferred investment options.
• The company will pursue regulatory approvals for the LIBERTY Endovascular Robotic Surgical System.

Key Dates